<DOC>
	<DOCNO>NCT00995930</DOCNO>
	<brief_summary>This study evaluate effect ACZ885 vascular function patient document atherosclerotic disease T2DM IGT .</brief_summary>
	<brief_title>Safety &amp; Effectiveness Vascular Structure Function ACZ885 Atherosclerosis Either T2DM IGT Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<criteria>Patients know atherosclerotic disease document diagnosis T2DM ≤ 14 year OR IGT HbA1c 6.0 % 10.0 % On stable statin therapy statin intolerant Patients eligible able participate study Contraindications MRI NYHA class IV Heart Failure NYHA class I III heart failure acute exacerbation 3 month prior screen Patients type 1 diabetes Acute infection HsCRP &gt; 30 mg/dL Aortic aneurysm ≥5cm Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Atherosclerosis ,</keyword>
	<keyword>Type 2 Diabetes Mellitus , T2DM ,</keyword>
	<keyword>Cardiovascular Diseases , ACZ885 , impair glucose tolerance , IGT , Canakinumab</keyword>
</DOC>